AIMS: There is heterogeneity in the reporting of procedural outcomes and complications following transcatheter aortic valve replacement (TAVR). Recently, new definitions have been proposed by the Valve Academic Research Consortium (VARC) in an effort to standardise these outcomes and improve the quality of future clinical research. The aim of this study is to report the procedural outcomes and complication rates following TAVR in a large sequential patient cohort using a balloon expandable valve according to the new VARC definitions. METHODS AND RESULTS: Three hundred and ten consecutive patients undergoing TAVR were assessed, including patients forming our early historical series at the infancy of TAVR. All complication rates were re-evaluated according to VARC definitions. Mean age was 82.2 ± 8.1 years and the Society of Thoracic Surgeons score was 9.4 ± 5.7%. Transfemoral 30-day mortality was 6.8% (3.8% in the second half of the cohort) and transapical 30-day mortality was 13.7% (9.4% in the second half of the cohort). Cardiovascular 30-day mortality was 7.4% and the composite safety endpoint at 30-days was 18.4%. Device success was 80% (post-procedural valve area ≤ 1.2 cm2 in 9.7%). Failure to deliver and deploy a valve occurred in only 3.5%, with 82% (nine cases) occurring in the first half of the experience. Of those who did not meet echocardiographic criteria for device success (valve area ≤ 1.2 cm2, transaortic gradient ≥ 20 mmHg or ≥ moderate aortic incompetence), 90% achieved a New York Heart Association class I/II. Life threatening bleeding complications occurred in 8.4%. In 7.7% of patients, red blood cell transfusions were given without evidence of overt bleeding. Major strokes occurred in 2.3% and acute kidney injury occurred in 6.5%. CONCLUSIONS: The VARC consensus guidelines provide a standardised reporting framework for clinical endpoints and complications post TAVR. We report the first series to our knowledge of 30-day outcomes using these definitions utilising a balloon expandable valve system.
AIMS: There is heterogeneity in the reporting of procedural outcomes and complications following transcatheter aortic valve replacement (TAVR). Recently, new definitions have been proposed by the Valve Academic Research Consortium (VARC) in an effort to standardise these outcomes and improve the quality of future clinical research. The aim of this study is to report the procedural outcomes and complication rates following TAVR in a large sequential patient cohort using a balloon expandable valve according to the new VARC definitions. METHODS AND RESULTS: Three hundred and ten consecutive patients undergoing TAVR were assessed, including patients forming our early historical series at the infancy of TAVR. All complication rates were re-evaluated according to VARC definitions. Mean age was 82.2 ± 8.1 years and the Society of Thoracic Surgeons score was 9.4 ± 5.7%. Transfemoral 30-day mortality was 6.8% (3.8% in the second half of the cohort) and transapical 30-day mortality was 13.7% (9.4% in the second half of the cohort). Cardiovascular 30-day mortality was 7.4% and the composite safety endpoint at 30-days was 18.4%. Device success was 80% (post-procedural valve area ≤ 1.2 cm2 in 9.7%). Failure to deliver and deploy a valve occurred in only 3.5%, with 82% (nine cases) occurring in the first half of the experience. Of those who did not meet echocardiographic criteria for device success (valve area ≤ 1.2 cm2, transaortic gradient ≥ 20 mmHg or ≥ moderate aortic incompetence), 90% achieved a New York Heart Association class I/II. Life threatening bleeding complications occurred in 8.4%. In 7.7% of patients, red blood cell transfusions were given without evidence of overt bleeding. Major strokes occurred in 2.3% and acute kidney injury occurred in 6.5%. CONCLUSIONS: The VARC consensus guidelines provide a standardised reporting framework for clinical endpoints and complications post TAVR. We report the first series to our knowledge of 30-day outcomes using these definitions utilising a balloon expandable valve system.
Authors: Thomas Pilgrim; Stefan Stortecky; Fabienne Luterbacher; Stephan Windecker; Peter Wenaweser Journal: J Thromb Thrombolysis Date: 2013-05 Impact factor: 2.300
Authors: Creighton W Don; Michael S Kim; Edward D Verrier; Gabriel S Aldea; Larry S Dean; Mark Reisman; Nahush A Mokadam Journal: J Invasive Cardiol Date: 2014-06 Impact factor: 2.022
Authors: Hoda Hatoum; Shelley Gooden; Megan Heitkemper; Kevin M Blum; Jason Zakko; Martin Bocks; Tai Yi; Yen-Lin Wu; Yadong Wang; Christopher K Breuer; Lakshmi Prasad Dasi Journal: Ann Biomed Eng Date: 2020-02-12 Impact factor: 3.934
Authors: Thi Dan Linh Nguyen-Kim; Ayhan Sahin; Simon H Sündermann; Anna Winklehner; Jürg Grünenfelder; Maximilian Y Emmert; Willibald Maier; Lukas Altwegg; Thomas Frauenfelder; Volkmar Falk; André Plass Journal: Interact Cardiovasc Thorac Surg Date: 2013-10-08
Authors: David M Holzhey; Martin Hänsig; Thomas Walther; Joerg Seeburger; Martin Misfeld; Axel Linke; Michael A Borger; Friedrich W Mohr Journal: Ann Cardiothorac Surg Date: 2012-07
Authors: Jennifer Mancio; Ricardo Fontes-Carvalho; Marco Oliveira; Daniel Caeiro; Pedro Braga; Nuno Bettencourt; Vasco Gama Ribeiro Journal: Front Cardiovasc Med Date: 2015-04-15
Authors: Katarzyna Czerwińska-Jelonkiewicz; Ilona Michałowska; Adam Witkowski; Maciej Dąbrowski; Ewa Księżycka-Majczyńska; Zbigniew Chmielak; Krzysztof Kuśmierski; Tomasz Hryniewiecki; Marcin Demkow; Janina Stępińska Journal: J Thromb Thrombolysis Date: 2014-05 Impact factor: 2.300